Figure 2.

Immunization with OVA-BiP/hsp70 complex elicits specific CTL responses in C57BL/6 mice. (a) Mice were injected once intradermally, and 7 days later splenocytes from immunized mice were restimulated in vitro as described in Materials and Methods. Results are shown as ⁵¹Cr release assays of splenocytes from mice immunized with OVA-BiP hybrid peptide/hsp70 complex, OVA peptide plus TiterMax (TM) adjuvant, OVA peptide plus hsp70, OVA-BiP hybrid peptide alone, OVA peptide alone, or hsp70 alone. Results are representative of more than 20 experiments. (b) CTL induction after immunization with OVA-BiP, BiP-OVA, mBiP-OVA, or mOVA-BiP plus hsp70. Results are representative of three experiments. (c) CTL induction after immunization with 15 μg (213 pmol) of hsp70 coupled with 12 μg (5.2 nmol), 1.2 μg (0.52 nmol), 0.6 μg (0.26 nmol), or 0.12 μg (53 pmol) of OVA-BiP peptide. Results are representative of two experiments. (d) CTL induction after immunization with 1.2 μg of OVA-BiP peptide complexed with 15 μg of hsp70, BiP, or gp96. Results are representative of two experiments. (e) CTL induction after immunization with hsp70 + OVA-BiP, BSA + OVA-BiP, mouse albumin (mAlb) + OVA-BiP, or hsp70 + OVA-BiP prepared by the incubation with 2 mM ATP instead of 2 mM ADP. The experiment were repeated three times with similar results. (f) CTL induction after immunization with hsp70 + OVA-BiP in wild-type C57BL/6 mice and in CD4^−/− mice. Results represent mean of two mice. Results are representative of two experiments.